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Abstract The activity of hepatic carnitine palmitoyltransferase
I (CPT-I) may be modulated by interactions with cytoskeletal
components [Velasco et al. (1998) J. Biol. Chem. 273, 21497^
21504]. We have studied whether the AMP-activated protein
kinase (AMPK) is involved in this process. AMPK stimulated
CPT-I in permeabilized hepatocytes but not in isolated liver
mitochondria. In addition, AMPK abrogated the inhibition of
CPT-I of isolated mitochondria induced by a cytoskeletal
fraction. These two effects of AMPK were not evident when
the kinase was inactivated by pretreatment with protein
phosphatase 2C. Cytokeratins 8 and 18 were phosphorylated
by AMPK in vitro and by incubation of intact hepatocytes with
5-aminoimidazole-4-carboxamide ribonucleoside, a cell-perme-
able activator of AMPK. These results provide the first evidence
that AMPK stimulates CPT-I by direct phosphorylation of
cytoskeletal components.
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1. Introduction
The AMP-activated protein kinase (AMPK) plays a major
role in the cellular response to metabolic stress [1,2]. AMPK is
activated by AMP and by phosphorylation by an upstream
kinase, which is itself activated by AMP [2,3]. Once activated,
AMPK phosphorylates and inactivates a number of regula-
tory enzymes involved in biosynthetic pathways, thereby pre-
venting further ATP utilization when ATP depletion ensues in
situations such as fuel limitation and hypoxia [2,4]. AMPK
plays an important role in the control of lipid metabolism.
Thus, AMPK phosphorylates and inactivates acetyl-CoA car-
boxylase (fatty acid synthesis), 3-hydroxy-3-methylglutaryl-
CoA reductase (sterol/isoprenoid synthesis) and hormone-sen-
sitive lipase (triacylglycerol/cholesteryl ester breakdown) [2].
Although several protein kinases can phosphorylate puri¢ed
acetyl-CoA carboxylase in vitro, there is good evidence dem-
onstrating that in intact hepatocytes and in the liver in vivo
AMPK is the major protein kinase responsible for the inacti-
vation of acetyl-CoA carboxylase by phosphorylation (cf. [2]).
Modulation of acetyl-CoA carboxylase activity by AMPK is
essential for the control of long-chain fatty acid oxidation
since malonyl-CoA, the product of the reaction catalyzed by
acetyl-CoA carboxylase, is the physiological inhibitor of car-
nitine palmitoyltransferase I (CPT-I), the key regulatory en-
zyme of long-chain fatty acid oxidation [5^7]. Activation of
AMPK has been shown to decrease malonyl-CoA levels and
to stimulate fatty acid oxidation in heart [8], skeletal muscle
[9] and liver [10].
Although evidence has accumulated during the last two
decades highlighting the physiological importance of malon-
yl-CoA inhibition of CPT-I [6,7], an additional mechanism of
control of CPT-I activity has been put forward. Studies using
permeabilized hepatocytes have shown that various agents
exert short-term e¡ects on CPT-I activity in parallel with
changes in the rate of long-chain fatty acid oxidation [5,11].
These changes in CPT-I activity are assumed to be mediated
by a malonyl-CoA-independent mechanism since they are very
stable and survive complete removal of malonyl-CoA from
the medium [12]. Recent observations indicate that this mal-
onyl-CoA-independent control of hepatic CPT-I activity may
rely on the modulation of interactions between mitochondria
and cytoskeletal components, most likely intermediate ¢la-
ments, so that disruption of the latter leads to de-inhibition
of CPT-I [13^15].
We have observed that the incubation of hepatocytes with
5-aminoimidazole-4-carboxamide ribonucleoside (AICAR), a
cell-permeable activator of AMPK, stimulates CPT-I, and this
stimulation partially survives cell permeabilization and exten-
sive washing of the permeabilized cells, pointing to a possible
malonyl-CoA-independent process [10]. The present work was
therefore undertaken to study the possible role of AMPK in
the malonyl-CoA-independent control of CPT-I activity.
2. Materials and methods
2.1. Materials
AMPK was puri¢ed from rat liver by immunoprecipitation with
speci¢c antibodies bound to protein A-Sepharose [4]. Recombinant
human protein phosphatase 2C [16] was a generous gift from Dr.
R.K. Beri (Zeneca Pharmaceuticals, Maccles¢eld, UK). Tetradecylgly-
cidate was kindly donated by Dr. J.M. Lowenstein (Brandeis Univer-
sity, Waltham, MA, USA). Puri¢ed cytokeratins 8 and 18 were from
ICN Pharmaceuticals (Costa Mesa, CA, USA). The anti-pan cytoker-
atin monoclonal antibody was from Sigma (St. Louis, MO, USA).
2.2. Assay of CPT-I activity
CPT-I activity was determined in isolated mitochondria as the mal-
onyl-CoA-sensitive incorporation of radiolabelled L-carnitine into
palmitoylcarnitine exactly as described before [12]. When CPT-I ac-
tivity was determined in suspensions of mitochondria containing a
total-cytoskeleton fraction, the latter was isolated as described in
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[15]. In other experiments, CPT-I activity was determined in permea-
bilized hepatocytes as the tetradecylglycidate-sensitive incorporation
of radiolabelled L-carnitine into palmitoylcarnitine as previously de-
scribed [12]. Hepatocytes were permeabilized with digitonin and then
extensively washed prior to determination of enzyme activity (‘two-
step assay’ in [10,12]).
2.3. Incubations with AMPK
To study the e¡ect of AMPK on CPT-I activity, isolated mitochon-
dria or digitonin-permeabilized hepatocytes were suspended in bu¡er
A, consisting of 50 mM Tris-HCl, pH 7.5, 50 mM NaF, 1 mM
EDTA, 5 mM sodium pyrophosphate, 1 mM dithiothreitol and 10%
(v/v) glycerol. This medium was supplemented with 0.2 mM AMP,
0.2 mM ATP and 5 mM MgCl2. After the addition of puri¢ed
AMPK, incubations were run for 10 min at 30‡C and CPT-I activity
was subsequently determined as described above. Reactions of AMPK
dephosphorylation were performed by washing 5 times the AMPK-
resin complex with bu¡er B (bu¡er A without the protein phosphatase
inhibitors NaF and sodium pyrophosphate) and further incubation
for 10 min at 30‡C in bu¡er B with 5 mM MgCl2 and 0.32 mg/ml
protein phosphatase 2C. Parallel controls were run in which the phos-
phatase was omitted from the incubations. The resulting AMPK is
designated as ‘washed AMPK’ in Figs. 1 and 2.
To study the phosphorylation of cytokeratins by AMPK, assays
were run in bu¡er A together with puri¢ed AMPK, 0.2 mM AMP,
0.2 mM [Q-32P]ATP (2 WCi/assay), 5 mM MgCl2 and 0.2 mg/ml puri-
¢ed cytokeratin 8 or 18. Positive controls were run in the presence of
0.2 mM SAMS peptide, whereas negative controls were performed in
the absence of AMPK or cytokeratins. After incubation for 15 min at
30‡C, samples were resolved by SDS-PAGE as described in [4].
2.4. Determination of the stoichiometry of cytokeratin phosphorylation
in intact hepatocytes
The stoichiometry of cytokeratin phosphorylation in intact hepato-
cytes was determined as described before [15] by simultaneously cal-
culating (i) the speci¢c radioactivity of the Q-phosphate of intracellular
ATP after labelling of the cells with 32Pi and separation of the adenine
nucleotides by HPLC; (ii) the amount of 32P incorporated into the
cytokeratin bands after labelling of the cells with 32Pi and immuno-
precipitation/SDS-PAGE of the cytokeratins; and (iii) the mass of
protein in those cytokeratin bands after immunoprecipitation of the
cytokeratins from 32P-free hepatocyte incubations and resolution by
SDS-PAGE in parallel with di¡erent amounts of puri¢ed cytokeratins
8 and 18.
2.5. Statistical analysis
Results shown represent the means þ S.D. of the number of experi-
ments indicated in each case. Incubations and enzyme assays were
always carried out in triplicate. Statistical analysis was performed
by Student’s t-test.
3. Results and discussion
3.1. AMPK stimulates CPT-I in permeabilized hepatocytes but
not in isolated liver mitochondria
Addition of puri¢ed AMPK to isolated liver mitochondria
did not exert any signi¢cant e¡ect on CPT-I activity (Fig. 1A).
In contrast, AMPK stimulated CPT-I activity in digitonin-
permeabilized hepatocytes by over 2-fold (Fig. 1B). The stim-
ulatory e¡ect of AMPK on CPT-I was not due to a non-
speci¢c e¡ect of the anti-AMPK antibody-protein A-Sephar-
ose complex, and was not evident when the kinase was pre-
treated with protein phosphatase 2C (Fig. 1B), a phosphatase
that has been shown to dephosphorylate and inactivate
AMPK [2,16]. These data indicate that extramitochondrial
cell components are required for the regulation of CPT-I by
AMPK. It has been shown previously that neither cyclic
AMP-dependent protein kinase nor protein kinase C exerts
any signi¢cant e¡ect on CPT-I activity in permeabilized hepa-
tocytes, whereas Ca2/calmodulin-dependent protein kinase II
caused a modest activation of CPT-I (approximately 40%)
[15]. Taken together, these results suggest that AMPK may
play a prominent role in the malonyl-CoA-independent con-
trol of hepatic CPT-I activity.
3.2. AMPK abrogates the inhibitory e¡ect of a cytoskeletal
fraction on CPT-I
In order to de¢ne the cell components that are su⁄cient for
the malonyl-CoA-independent control of CPT-I to occur, a
simple reconstitution system was used consisting of isolated
mitochondria together with a cytoskeletal fraction (cf. [15]).
As shown in Fig. 2, the inhibition of CPT-I produced
by exposure of isolated mitochondria to the cytoskeletal
fraction was reverted by addition of exogenous AMPK.
This e¡ect was prevented by pretreatment of the kinase with
protein phosphatase 2C (Fig. 2). Hence it is likely that AMPK
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Fig. 1. AMPK stimulates CPT-I in permeabilized hepatocytes but not in isolated liver mitochondria. A: CPT-I activity in isolated liver mito-
chondria. B: CPT-I activity in permeabilized hepatocytes. ‘Resin’ denotes the anti-AMPK antibody-protein A-Sepharose complex. Results cor-
respond to four di¡erent experiments. One hundred percent values of CPT-I activity (in nmol/min/mg protein) were 7.86 þ 1.34 in isolated mito-
chondria and 2.09 þ 0.40 in permeabilized hepatocytes. *P6 0.01 vs. incubations with no additions.
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stimulates CPT-I by acting on certain cytoskeletal compo-
nents.
3.3. AMPK phosphorylates cytokeratins 8 and 18 in vitro and
in intact hepatocytes
We have recently shown that incubation of hepatocytes
with colchicine (a microtubule disrupter) and cytochalasin (a
micro¢lament disrupter) has no e¡ect on CPT-I activity,
whereas cell exposure to 3,3P-iminodipropionitrile (an inter-
mediate ¢lament disrupter) produces a signi¢cant stimulation
of CPT-I [15]. This and other observations indicate that in-
termediate ¢laments may be the cytoskeletal components in-
volved in the malonyl-CoA-independent modulation of CPT-I
activity [15]. AMPK was unable to signi¢cantly (less than 0.05
mol phosphate per mol protein) phosphorylate puri¢ed tubu-
lin (microtubules) and actin (micro¢laments). In contrast, pu-
ri¢ed cytokeratins 8 and 18, the major components of liver
intermediate ¢laments [17], were readily phosphorylated by
AMPK in vitro (Fig. 3A). These results are consistent with
the hypothesis that AMPK activates CPT-I in a malonyl-CoA
independent manner by modi¢cation of the intermediate ¢la-
ment organization.
The phosphorylation pattern of puri¢ed cytokeratins in vi-
tro may not re£ect their phosphorylation status in a more
physiological, whole-cell system (cf. [18,19]). Intact hepato-
cytes were labelled with 32Pi and cytokeratins were immuno-
precipitated after exposing the cells to AICAR. The protein
phosphatase inhibitor okadaic acid was used as a positive
control since it has been shown to induce cytokeratin hyper-
phosphorylation [15]. As shown in Fig. 3B, cytokeratins 8 and
18 were phosphorylated by okadaic acid and ^ to a lower
extent ^ by AICAR. Since phosphorylation of cytokeratins
8 and 18 has been shown to induce the disruption of liver
intermediate ¢laments [17^19], these data further support
the hypothesis that AMPK may be involved in the control
of cytoskeletal dynamics.
In both the in vitro (Fig. 3A) and the whole-cell experi-
ments (Fig. 3B) the extent of phosphorylation of cytokeratin
8 was higher than that of cytokeratin 18. The stoichiometry of
phosphorylation of the puri¢ed cytokeratins by AMPK in
vitro (Fig. 3A) was signi¢cantly lower than that of the AI-
CAR-induced phosphorylation of cytokeratins in intact hepa-
tocytes (Fig. 3B). We do not know the reason for this di¡er-
ence although it may be due, at least in part, to the way in
which the in vitro assays are performed. The solubility of
cytokeratins in aqueous solutions is extremely low, and they
tend to form ¢lamentous complexes in vitro [17]. The AMPK
used for the phosphorylation is present in an immune complex
and this, combined with the low solubility of the cytokeratins,
might prevent, or hinder, the kinase from phosphorylating
some of the sites within the cytokeratins. Whatever the
reason, it is clear that AMPK phosphorylates cytokeratins
8 and 18 in vitro and that AICAR mimics this e¡ect in hepa-
tocytes.
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Fig. 3. AMPK phosphorylates cytokeratins 8 and 18 in vitro and in intact hepatocytes. A: Phosphorylation of puri¢ed cytokeratins 8 and 18 in
vitro. B: Phosphorylation of cytokeratins 8 and 18 in intact hepatocytes. After labelling with 32Pi, hepatocytes were incubated for 15 min in
the absence or presence of 0.5 mM AICAR and/or 0.5 WM okadaic acid (OA). Open bars: cytokeratin 8; hatched bars: cytokeratin 18. Note
the di¡erent scales on the y-axes. Results correspond to four di¡erent experiments. *P6 0.01 vs. incubations with no additions.
Fig. 2. AMPK abrogates the inhibitory e¡ect of a cytoskeletal frac-
tion on CPT-I. Isolated liver mitochondria (1.5^2.0 mg protein/ml)
were preincubated for 10 min in the absence (3) or presence (+) of
a cytoskeletal fraction (0.05^0.06 mg protein/ml). AMPK was subse-
quently added (+) or not (3) to the incubations. The kinase had
been pretreated (+) or not (3) with protein phosphatase 2C. Results
correspond to four di¡erent experiments. *P6 0.01 vs. incubations
with no additions.
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3.4. Possible physiological implications
The physiological importance of the malonyl-CoA-inde-
pendent control of hepatic CPT-I activity is still unclear. In
vitro and in vivo experiments indicate that the dynamics of
mitochondria in living cells may be modulated by speci¢c
interactions with the cytoskeleton [20,21]. Since the organiza-
tion of intermediate ¢laments changes dramatically in a num-
ber of liver pathologies [21,22], it might be expected that CPT-
I activity would be a¡ected in parallel under these conditions.
Indeed, this has been shown to occur in transformed liver cells
[23]. Despite this, it is obvious that the existence of malonyl-
CoA-independent regulation of CPT-I does not diminish the
importance of malonyl-CoA as a physiological modulator of
CPT-I activity [6,7]. It seems likely, however, that the malon-
yl-CoA-dependent and malonyl-CoA-independent control of
hepatic CPT-I by AMPK may operate in concert ([10] and the
present report).
Although it is widely accepted that AMPK plays a pivotal
role in the regulation of energy metabolism [2], recent evi-
dence indicates that this kinase may regulate a wider array
of cellular functions such as gene expression [24,25], extracel-
lular matrix-evoked cell growth [26] and cytoskeletal dynamics
(the present report). Furthermore, the possibility that AMPK
may control CPT-I activity by phosphorylating cytoskeletal
components supports the emerging regulatory role of the cy-
toskeleton in intracellular signalling [21,22,27].
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